Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Inclusion Criteria: * Adult male or female subjects between 18 and 70 years old * Diagnosed history of chronic rhinosinusitis without nasal polyps (CRSsNP) defined as per EPOS Guidelines. * Moderate to severe baseline SNOT-20 GAV score (\> 20) * Willingness to stop nasal saline irrigation and drug therapy for CRSsNP (restart later on possible) Exclusion Criteria: * Subjects with local pathology that would compromise the ability to either administer the device or assess the benefits/risks (e.g. mucocele, antrochoanal polyp, facial trauma, radiation injury, or birth defect) * Systemic corticosteroids if not stop for 14 days before study enrolment * Subjects suffering from insufficiently controlled asthma * Subjects suffering from insufficiently controlled allergic rhinitis (AR) * Subjects with prior sinus operations within the last 4 months * Subjects with known primary ciliary dyskinesia/cystic fibrosis * Subjects with serious underlying medical condition * Ongoing oncological treatments * Known hypersensitivity to materials in direct contact with the skin * Metal or metal-like implant (incl. ceramic) located in the head or neck area. Unremovable hearing aids * Patients with implanted cardiac pace-maker * Women who are pregnant or breast feeding * Known or suspected non-compliance, drug or alcohol abuse, * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant